MetrioPharm veröffentlicht Studiendaten, die die Wirkung einer Host-Directed Therapy in COVID-19 zeigen
31 janv. 2024 05h00 HE
|
AKAMPION
Ergebnisse stammen aus der klinischen Studie CT-05 an 131 hospitalisierten Patienten mit COVID-19Die Daten zeigen, dass MetrioPharms Leitsubstanz MP1032 eine mit Remdesivir vergleichbare Wirksamkeit...
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
31 janv. 2024 05h00 HE
|
AKAMPION
Results of clinical trial CT-05 in 131 hospitalized patients with COVID-19Trial data demonstrate that MetrioPharm´s lead compound MP1032 has comparable efficacy to remdesivir with several additional...
Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet
24 juil. 2023 21h39 HE
|
Elevar Therapeutics
FORT LEE, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
The Lancet Commission Formally Recognizes the Term ‘Profound Autism’
07 déc. 2021 09h00 HE
|
Autism Science Foundation
New York, Dec. 07, 2021 (GLOBE NEWSWIRE) -- The Autism Science Foundation (ASF), a nonprofit organization dedicated to supporting and funding innovative autism research, today calls attention to the...
New Report by The Lancet Commission Finds Hearing Loss in Midlife To Be the Largest Modifiable Risk Factor for Dementia
20 août 2020 09h05 HE
|
HearingLife Canada
TORONTO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- HearingLife, Canada’s largest group of hearing centres, announced today that a new report in The Lancet, one of the world’s most-prestigious medical...